AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Omada Health: Morgan Stanley initiates at 'Overweight' Rating, The Target Price is $25
ByAinvest
Tuesday, Jul 1, 2025 12:00 pm ET1min read
Morgan Stanley initiates coverage on 'Overweight' rating on Omada Health(OMDA).
The target price is $25.
[Recent Rating]
| Date | Agency | Change | Rating | Rating （previously） | Target Price | Target Price（previously） |
|---|---|---|---|---|---|---|
| 2025-07-01 | Goldman Sachs | Initiates Coverage On | Buy | -- | $29 | $-- |
| 2025-07-01 | Canaccord Genuity | Initiates Coverage On | Buy | -- | $27 | $-- |
| 2025-07-01 | Morgan Stanley | Initiates Coverage On | Overweight | -- | $25 | $-- |
| 2025-07-01 | Needham | Initiates Coverage On | Buy | -- | $23 | $-- |
| 2025-07-01 | Barclays | Initiates Coverage On | Overweight | -- | $21 | $-- |
| 2025-07-01 | JP Morgan | Initiates Coverage On | Overweight | -- | $20 | $-- |
[Company Profile] Omada Health, Inc. was incorporated under the laws of the State of Delaware on April 25, 2011. They deliver virtual care between doctor’s visits, providing an engaging, personalized, and integrated experience for members that is designed to improve their health while delivering value for the employers, health plans, health systems, pharmacy benefit managers, and other entities.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet